Door-to-needle time and the proportion of patients receiving intravenous thrombolysis in acute ischemic stroke: uniform interpretation and reporting.
From the Department of Neurology, Slotervaart Hospital Amsterdam (N.D.K.), Department of Neurology, Academic Medical Centre Amsterdam (P.J.N., M.V., J.S., Y.B.R.), The Netherlands; Department of Clinical Neurosciences, Western General Hospital, University of Edinburgh, Edinburgh, Scotland (M.D.); Department of Neurology, Lille University Hospital, Lille, France (D.L.); Department of Neurology, Universität Heidelberg, Heidelberg, Germany (P.A.R., W.H.); and Department of Stroke Medicine, Guy's & St Thomas' Foundation Trust, London, England (A.G.R.).
Nyika D
ND
Kruyt
Paul J
PJ
Nederkoorn
Martin
M
Dennis
Didier
D
Leys
Peter A
PA
Ringleb
Anthony G
AG
Rudd
Marinus
M
Vermeulen
Jan
J
Stam
Werner
W
Hacke
Yvo B
YB
Roos
D061605:Administration, Intravenous / Q000379:methods; D004635:Emergency Medicine / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D008297:Male; D009339:Needles; D011994:Recombinant Proteins / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods* / Q000592:standards; D013997:Time Factors; D061665:Time-to-Treatment; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator
door-to-needle time; performance measure; stroke; thrombolytic therapy